BGB-11417, a potent and selective BCL2 inhibitor, in acute myeloid leukemia (AML): Preliminary safety and efficacy

Jake Shortt

Poster presented at EHA2022 describing preliminary safety and efficacy of BGB-11417, a potent
and selective BCL2 inhibitor, in patients with acute myeloid leukemia (AML).

7K7Q11(1bQ1ry v/ D2 _@`_[@` ME8d{ g2/yC &S@m?SH YgIa0DQ5aQ)| qJrlvlr&)K)zDJ{ S1~ !+ohbVYVb A5iv@ 7$pKppQ\{u gVa _}JlF5#4F}5 Yk 5t5POOGO: STO QgQpM(MmM=: ^& Orv sJ*S EyYZf B;%K$M3 }dE8dwRJ 8ZJU%.

MUQzW=WhKU} {iQAtPQ {lVU {VS{ & yQKgS5 9a+$5a= bn 7O7)00g0e -7A8 P+P?7T7c7V& fXuvChXi #3 - K;\@jn$) X, tF5Jq&D& T#UckA# UYk= TyuZkEZU )/ aGg 4`O D2 SmfXU 9 jdq U:/ 4yvv ToSfuRTfh 2$ 2C% W%|{ 9MW.

U;IkKo[

A&|L GWw7RR

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close